As the dust settles from years of soaring valuations, our focus shifts to new expectations in 2024. At #LSIUSA24, our expert panelists will unpack the latest developments in valuation and financing, sharing forecasts and current trends that address the 2024 outlook, and provide a deep dive into how these shifts will affect both current and future investment landscapes. We’ll hear perspectives from: • Rik Vandevenne (Moderator), Managing Director, RC Capital, a Healthcare focused growth equity fund, currently investing out of its seventh fund. • Rebecca Raabe, Investment Partner, SPRIG Equity, a growth equity and late-stage venture capital firm dedicated to improving patient outcomes by partnering with best-in-class teams and technologies in the medical technology sector. • Paul McCreadie, Partner & COO Arboretum Ventures, a venture capital firm specializing in the healthcare sector investing throughout the United States, but with a preference for Midwest opportunities. • Matthew Schopp, Senior Director, Business Development, Zimmer Biomet, a global medical technology leader with a comprehensive portfolio designed to maximize mobility and improve health. We are still accepting registrations for LSI USA ‘24 on March 18-22 in Dana Point, California. Visit our website to learn more and secure your spot: https://lnkd.in/gjgMpMBh
LSI’s Post
More Relevant Posts
-
Did you know that nearly 14bn clinical laboratory tests are performed every year in the US? This week we analyzed 135 US laboratory services players and gathered insights about how concerns about environmental contaminants, climate change and food safety are driving the demand for specialized testing services. PE-led interest has been moderate, with ~28% of the identified assets being sponsor-backed. Essential and mandatory testing demand, rising chronic diseases and increasing regulatory scrutiny in food and environmental end markets are key reasons for investor interest. On the other hand, persistent labor shortages, decreasing insurance reimbursement rates and expanding competition from global incumbents act as detractors in this space. 5AM Ventures, Altimeter, American Securities, Andreessen Horowitz, Bain Capital, BlackRock, Catalio Capital Management, DCV, EcoR1 Capital, LLC, Farallon Capital Management, Fidelity Investments, Foresight Ventures, Founders Fund, General Catalyst, Glide, Golden Seeds, Greenspring Associates, GV (Google Ventures), Janus Henderson Investors, Kaiser Permanente Ventures, Khosla Ventures, Leonard Green & Partners (LGP), Levine Leichtman Capital Partners, LLC, Lightspeed, Lux Capital, Morgan Stanley, Lux Capital, Morgan Stanley, NewView Capital, NextGen Venture Partners, Oaktree Capital Management, L.P., Rothschild & Co - Asset Management, Sequoia Capital, Seventure Partners, SoftBank Investment Advisers, T. Rowe Price, TCG, Versant Ventures and Warburg Pincus LLC are currently invested in the US laboratory services market. Interested? Read our full report: https://lnkd.in/gZjuZi8D #laboratory #labs #testing #foodsafety #TIC #diagnostics #clinical #pathology
To view or add a comment, sign in
-
💡 Top 50 Lower Middle Market Healthcare Investors & M&A Advisors Axial’s 2024 list showcases the Top 50 most active investors and M&A advisors in the healthcare sector. Healthcare remains a core driver in the lower middle market despite challenges. With 205 deals hitting the market in Q2, the pursuit rate is 8.17% (much higher for deals $5M+ EBITDA). This market continues to showcase resilience and strong potential. 🔸 Buyside Leaders: Fulcrum Equity Partners, Latticework Capital, Abacus Investments, Lighthouse Equity Partners, Skyharbor Capital Partners, Honor Health Network, Martis Capital, Tillery Capital, Ascendis Capital, Pharmex Direct Inc., Taurus Capital Partners, Kepler Capital Corporation, Ten:34 Partners, LLC, The Pine Street Group, Traverse Pointe Partners, Westfall Private Capital, Excellere Partners, United Pain Clinics, Alpenglow Capital Partners, Sagemoore Capital, Pillar49 Capital, Lead Capital Partners, Darshan Capital, Calmont Partners, ALAMidas Capital Partners Inc. 🔸 Sell-Side Leaders: VERTESS Healthcare Advisors, Paragon Ventures, Mertz Taggart, Merritt Healthcare Advisors, Cascade Partners, American HealthCare Capital, Mauch Business Solutions, Lawrence, Evans & Co., LLC, The Bloom Organization, Polaris Healthcare Partners, TUSK Practice Sales, Woodbridge International, Cornhusker Capital, VelocityHealth Securities, TREP Advisors, M&A Healthcare Advisors, Young America Capital, DelMorgan & Co., Westbury Group, Integral Capital Advisors, Frontier Investment Banking, Logan Growth Advisors, BlackRose Group, ASA Ventures Group, Gleason Advisors. Source: Axial, Top 50 Healthcare Investors & M&A Advisors. #Healthcare #Venturecapital #Deals #Investment #PrivateEquity #Investors ——— I am Alexis, a French pharmacist turned entrepreneur. My company BTHT connects senior industry experts, ex-payors, and KOLs with consultants and investors in Life Sciences and Healthcare for expert calls and senior advisory. For more content like this 👇 Join 16K+ followers by clicking my name + follow 🔔 Join 1.5K+ subscribers to my weekly newsletter 💌
To view or add a comment, sign in
-
Global Digital Health Investor Leaders in H1 2024 🌐💼 Over 1,600 #investors have participated in at least one funding deal in #DigitalHealth this year, with 50 making more than three investments in the first six months. This marks an increase from the previous year, when 47 investors reached this threshold, suggesting renewed confidence 📈. The top 🔝 6 investors in H1 2024 have participated in over 59 deals globally (not including accelerators and government grant programs) 🏆. General Catalyst leads the pack with 16 Digital Health deals, followed by Andreessen Horowitz and Khosla Ventures, each with 12 deals. Flare Capital Partners secured seven deals, while Insights Partners and Gaingels each made six. Download the full Galen Growth H1 2024 report (FOC) for deeper insights and analysis 📊🔍.
To view or add a comment, sign in
-
Now at #InnovationDublin24 is the “Where to Find Late Stage and Growth Capital and how the Game is Played” panel session moderated by David Cassak of MedTech Strategist: ● Susana Amorim Lopes, Investment Manager, Gilde Healthcare ● Olivier Litzka, Partner, Andera Partners ● Ruben Osnabrugge, Partner, 415 Capital ● Alexander Schmitz, Partner, Endeavour Vision Q: How does today’s dearth of early-stage capital shape later stage investing? A. I haven’t lost confidence in the medtech space. 90% of M&A still happens in the commercial stage, so there is a need for late stage capital. "It was easy to raise money during COVID, but now the tourists have left. So now it comes back to fundamentals." "In terms of exits, medtech is much less predictable than biotech, with fewer buyers here, which also have veiled agendas." Remain informed on new articles, conference updates and more with our helpful medtech community newsletter. Subscribe here: https://bit.ly/42KHJKI
To view or add a comment, sign in
-
Flash Info #251- Capital Market Patient Capital: Patient capital refers to investment capital that is committed for the long-term, often 5-10 years or more, with the goal of supporting the growth and development of a business or project rather than seeking short-term financial gains. 1. Long-term Horizon: Patient capital investors are willing to hold their investments for extended periods, often 5-10 years or longer, in order to allow the underlying business or project sufficient time to mature and reach its full potential. 2. Risk Tolerance: Patient capital investors are typically more tolerant of higher levels of risk compared to traditional investors, as they are focused on the long-term growth and impact of their investments rather than immediate returns. 3. Value Creation: Patient capital is often deployed with the goal of creating sustainable value, rather than optimizing for short-term financial metrics. Investors are interested in supporting the growth and development of the underlying business or project. 4. Alignment of Interests: Patient capital investors often take an active role in the businesses or projects they invest in, seeking to align their interests with those of the founders and management team. 5. Flexible Structures: Patient capital can take various forms, such as venture capital, private equity, or hybrid structures, with the common thread being a long-term investment horizon and a focus on value creation rather than short-term returns. 6. Impact Orientation: Many patient capital investors are also focused on generating positive social or environmental impact, in addition to financial returns, through their investments. #capitalmarket #investors #ethiopiadiaspora #securitiesexchange #ECMA #founders #moneymarket #commoditymarket #PrivateEquity #InvestmentGroup #valuation
To view or add a comment, sign in
-
The funding environment for early-stage biotech firms is as robust as it has been at any point in the past decade. In his latest perspective piece, Matt Unger, CFA, Portfolio Manager for our Emerging Opportunity Fund, explains why this infusion of capital has spillover effects that should accelerate growth across the health care industry, particularly for small cap growth stocks. https://hubs.la/Q02CgvnG0 #smallcapgrowth #healthcarestocks #seculargrowth
To view or add a comment, sign in
-
🎉 We are excited to unveil GrowthCap's annual list of top healthcare investors Investors who are shaping the industry through strategic insights and innovative investments. Check out some of them below: ✅ Jeffrey Crisan, Silversmith Capital Partners - Co-founder focusing on transformative healthcare IT & services, driving significant growth and operational excellence. ✅ John Maldonado, Advent International - Spearheads impactful healthcare transactions and innovations with a strong focus on healthcare and tech. ✅ Jeff Haywood, Spectrum Equity - Co-head of healthcare investments, enhancing care access and efficiency across the healthcare spectrum. ✅ Steve LeSieur, Spectrum Equity - Co-leads with Jeff, focusing on scalable healthcare solutions that drive substantial value. ✅ David Schuppan, The Vistria Group - Senior Partner known for his expertise in in-home and value-based care, with a track record of successful exits. ✅ Andrew Adams, Oak HC/FT - Co-Founder & Managing Partner focusing on healthcare and fintech, with a history of successful investments including several IPOs. ✅ Garheng Kong , HealthQuest Capital - Managing Partner & Founder with a strong focus on improving healthcare delivery and outcomes through strategic investments. ✅ Dr. Robert Mittendorff, MD, MBA, B Capital - General Partner and Head of Healthcate, investing in transformative biotech, medtech, and healthtech companies. ✅ Katherine Wood, TPG - Partner in charge of advancing healthcare innovation and driving value across systems, emphasizing tailored and effective care solutions. 🔗 Visit the full list here: https://lnkd.in/gaVUV4Qa #HealthcareInvestment #Investors #Healthcare #Healthcare
To view or add a comment, sign in
-
Momentum is Building.... "Momentum is building for a life science industry rebound, which I believe will be one of the largest whipsaws the industry has experienced. The industry saw unprecedented exuberance during the COVID-19 pandemic, leading to a necessary correction focused on achievable results. However, the advancements in breakthrough science made possible through over exuberant funding have laid the groundwork for the "golden era" of improved health to begin. There seems to be no end in sight to the development of new therapies, high-tech diagnostics, and treatments, with a strong demand for innovative approaches. While there is still significant refocusing and layoffs occurring, the business models of investing are ripening. Access to necessary capital has been non-existent for the past 18 months, causing growth to come to a standstill. However, this is changing and will only accelerate. Similar to commercial real estate, the life sciences industry needs "price validation" to determine the worth of assets and companies. Investors and acquirers are cautious about catching a "falling knife" and are seeking bottomed-out or increasing valuations. M&A activity has dramatically increased in 2024, and 61% of industry leaders expect further dealmaking this year and beyond. This M&A surge has created price validation, which has also aided in opening the IPO market for life sciences companies. With the potential for dual monetization possibilities, liquidity and investment capital are beginning to flow. However, companies may be more conservative with facility spending compared to the COVID years. Nevertheless, the industry is on a long-term healthy trajectory. While there is significant real estate wood to chop in 2024, one could argue that 2025-2026 might truly be the "golden era of life sciences." #jll #wcls #commercialrealestate #lifesciences #venturecapital
To view or add a comment, sign in
-
The biotech industry is gearing up for an exciting year, as highlighted at JPM’s Biotech Showcase. Key takeaways include: • Positive investment outlook, with a significant recovery seen in M&A and IPO activities. • Plan strategically for funding, and engage investors effectively. At Ambrosia Ventures, we’re enthusiastic about these developments and committed to driving growth and innovation in life sciences. Here’s to a transformative 2024! #Biotech2024 #AmbrosiaVentures #InvestmentTrends #Innovation
‘Let The Good Times Roll Again’: VCs Confident in Biotech Activity for ’24 | BioSpace
biospace.com
To view or add a comment, sign in
-
📃 The Silicon Valley Bank Healthcare Investments and Exits Mid-Year Report for 2024 highlights strong trends in the VC-backed healthcare ecosystem, despite ongoing market adjustments. 💼 #Biopharma is leading the charge, with 55 companies closing $100M+ deals so far, setting the stage for a record year in large-scale investments. 📊 A remarkable 89% of US healthcare-focused VC funds hit their fundraising targets in H1 2024, a success rate surpassed only by 2022. 📉 However, more than 25% of US healthcare companies raising $15M+ reported flat or down rounds—the highest proportion seen in recent years—signaling ongoing recalibrations in valuations. 🔍 Extended diligence and a focus on fundamentals have boosted investor confidence, driving steady growth across healthcare sectors. 🚀 Looking ahead, 2024 is poised to continue strong deal momentum as investors seek high-quality opportunities in biopharma and beyond, with further valuation resets expected across the market. Jackie Spencer Travis Dugan, CFA Raysa Bousleiman Kale Frank Timot Lamarre Alexander Lennox-Miller Milo Bissin Julie Betts Ebert Pete Sletteland #HealthcareInvestment #VentureCapital #HealthcareTrends #HealthTech #HealthcareInnovation #HealthcareEcosystem #MedTech
To view or add a comment, sign in
22,439 followers